Portfolio concentration
As of February 28, 2026 · N-PORT
Holdings
125
Top-10 weight
41.74%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
39
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
927.9
Holdings
As of February 28, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | LILLY ELI and CO | — | 408,000 | $429.21M | 6.93% |
| 2 | DANAHER CORP | — | 1,880,000 | $396.00M | 6.39% |
| 3 | BOSTON SCIENTIFIC CORP | — | 4,850,000 | $372.72M | 6.01% |
| 4 | JOHNSON&JOHNSON | — | 1,400,000 | $347.80M | 5.61% |
| 5 | ABBVIE INC | — | 1,140,000 | $264.57M | 4.27% |
| 6 | Fidelity Securities Lending Cash Central Fund | — | 224,531,147 | $224.55M | 3.62% |
| 7 | Ascendis Pharma A/S | — | 716,000 | $167.19M | 2.70% |
| 8 | UCB SA | — | 540,000 | $160.98M | 2.60% |
| 9 | GILEAD SCIENCES INC | — | 1,080,000 | $160.87M | 2.60% |
| 10 | MERCK & CO | — | 1,280,000 | $158.49M | 2.56% |
| 11 | ARGENX SE SPONSORED ADR | — | 200,000 | $153.38M | 2.48% |
| 12 | EDWARDS LIFESCIENCES CORP | — | 1,600,000 | $138.35M | 2.23% |
| 13 | CVS HEALTH CORP | — | 1,500,000 | $119.85M | 1.93% |
| 14 | ALNYLAM PHARMACEUTICALS INC | — | 340,000 | $113.19M | 1.83% |
| 15 | THERMO FISHER SCIENTIFIC INC | — | 212,000 | $110.48M | 1.78% |
| 16 | COGENT BIOSCIENCES INC | — | 2,560,000 | $99.46M | 1.60% |
| 17 | MCKESSON CORP | — | 95,000 | $93.80M | 1.51% |
| 18 | BRIGHTSPRING HEALTH SERVICES INC | — | 2,080,000 | $86.17M | 1.39% |
| 19 | MODERNA INC | — | 1,600,000 | $85.71M | 1.38% |
| 20 | INSMED INC | — | 560,000 | $83.62M | 1.35% |
| 21 | VIRIDIAN THERAPEUTICS INC | — | 2,819,500 | $82.84M | 1.34% |
| 22 | UNITEDHEALTH GRP | — | 280,000 | $82.12M | 1.33% |
| 23 | NUVALENT INC-A | — | 760,000 | $77.48M | 1.25% |
| 24 | ROCHE HOLDINGS AG (GENUSSCHEINE) | — | 160,000 | $76.14M | 1.23% |
| 25 | CENCORA INC | — | 200,000 | $74.43M | 1.20% |
| 26 | ROYALTY PHARMA PLC | — | 1,500,000 | $69.32M | 1.12% |
| 27 | INSULET CORP | — | 270,000 | $66.58M | 1.07% |
| 28 | WAYSTAR HOLDING CORP | — | 2,500,000 | $64.12M | 1.03% |
| 29 | VAXCYTE INC | — | 1,000,000 | $61.74M | 1.00% |
| 30 | CARIS LIFE SCIENCES INC | — | 3,050,000 | $61.43M | 0.99% |
| 31 | STRYKER CORP | — | 150,000 | $58.12M | 0.94% |
| 32 | XENON PHARMACEUTICALS INC | — | 1,290,000 | $55.77M | 0.90% |
| 33 | REPLIGEN CORP | — | 428,000 | $55.10M | 0.89% |
| 34 | VEEVA SYSTEMS-A | — | 300,000 | $54.60M | 0.88% |
| 35 | PRIVIA HEALTH GROUP INC | — | 2,280,000 | $54.15M | 0.87% |
| 36 | PRAXIS PRECISION MEDICINES INC | — | 160,000 | $53.88M | 0.87% |
| 37 | LEGEND BIOTECH CORP SPON ADR | — | 2,800,000 | $53.20M | 0.86% |
| 38 | CRINETICS PHARMACEUTICALS INC | — | 1,280,000 | $52.61M | 0.85% |
| 39 | INTUITIVE SURGICAL INC | — | 100,000 | $50.35M | 0.81% |
| 40 | MEDLINE INC-A | — | 1,000,000 | $47.51M | 0.77% |
| 41 | CG ONCOLOGY INC | — | 800,000 | $47.04M | 0.76% |
| 42 | CENTESSA PHARMACEUTICALS LTD ADR | — | 1,650,000 | $44.32M | 0.72% |
| 43 | DISC MEDICINE INC | — | 650,000 | $43.30M | 0.70% |
| 44 | SPYRE THERAPEUTICS INC | — | 940,000 | $40.43M | 0.65% |
| 45 | STRUCTURE THERAPEUTICS INC ADR | — | 620,000 | $39.05M | 0.63% |
| 46 | ALIGNMENT HEALTHCARE INC | — | 2,000,000 | $38.44M | 0.62% |
| 47 | ENLIVEN THERAPEUTICS INC | — | 1,280,000 | $38.00M | 0.61% |
| 48 | VERACYTE INC | — | 1,030,144 | $37.69M | 0.61% |
| 49 | CYTOKINETICS INC | — | 600,000 | $37.33M | 0.60% |
| 50 | ROIVANT SCIENCES LTD | — | 1,280,000 | $37.04M | 0.60% |
1 / 3
Next ›
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.